NEW ZEALAND DATA SHEET

1 MERIEUX INACTIVATED RABIES VACCINE (MIRV) 2.5 IU SUSPENSION FOR INJECTION

Merieux Inactivated Rabies Vaccine (MIRV) suspension for injection.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains inactivated Wistar rabies virus strain PM/W1381503-3M Rabies vaccine.

The potency of the reconstituted vaccine is not less than 2.5 IU, the WHO International Standard per dose (1 mL). Each vial contains, in addition, between 100 and 150 microgram of neomycin and up to 70 mg of human serum albumin.

MIRV is lyophilised, stabilised suspension of inactivated Wistar rabies virus strain PM/W1381503-3M. It is cultured on human diploid cells and inactivated by β-propiolactone. These human diploid cells are a cell line derived from human embryonic lung tissue in the 1960s.

The manufacture of this product includes exposure to bovine materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Vial (powder for reconstitution).

1 mL solvent (distilled water).

The powder is pinkish beige to orangey yellow. After reconstitution with the diluent supplied it turns a pinkish colour due to the presence of phenol red.
4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
Pre-exposure immunisation in persons at special risk of contracting rabies. Post exposure immunisation against rabies.

4.2 DOSE AND METHOD OF ADMINISTRATION

Dose

One dose consists of 1 mL of vaccine administered by the intramuscular route, in the deltoid area for adults and children or the anterolateral area of the thigh muscle in infants and toddlers.

The vaccination schedule should be adapted in accordance with the circumstances of the exposure and the individual’s rabies immune status. For further information, refer to the current Immunisation Handbook.

Product is for single use in one patient on one occasion only. Discard any residue.

Pre-Exposure Vaccination

- Primary vaccination: 3 injections at day 0, day 7, and day 21 or day 28 (as per WHO recommendations)

Regular serology testing of neutralising antibodies is recommended to assess seroconversion of individuals at increased risk of exposure to rabies virus, with a frequency adapted to that risk. When antibody titre is below acceptable level, a booster dose is needed. For further information on booster dose recommendations, refer to the current Immunisation Handbook.

According to the Immunisation Handbook, WHO current recommendations state that booster doses are not required for persons who are travelling to, or living in, an area of high rabies risk and who have completed a primary course, either pre- or post-exposure, using currently available cell culture derived vaccine.

Post exposure Treatment

Post-exposure treatment consists of local treatment of the wound, initiated as soon as possible after an exposure, followed by the administration of the vaccine and of passive immunisation, if indicated.

Immunisation

The vaccination must be administered under medical supervision and should be started as soon as possible after exposure.
The treatment must be adapted according to the type of contact and the immunisation status of the subject. For further information, refer to the current Immunisation Handbook.

_Vaccination of Non-Immunised Individuals_

_Administration of immunoglobulin_

In the case of severe types of exposure, rabies immunoglobulin should be given in association with the vaccine for non-immunised individuals:

On day 0, a complementary passive immunisation is required using:

- Human rabies immunoglobulin (HRIG): 20 IU/kg body weight

As much as possible should be infiltrated around the wounds. The remainder should be administered by deep intramuscular injection at a site distant from the vaccine injection site. If possible, the vaccine should be injected contra-laterally to the immunoglobulin administration sites.

_Automation of vaccine_

Vaccine should be administered on day 0, day 3, day 7 and day 14 (4 injections of 1 mL). The posology is the same for adults and children.

_Vaccination of Previously Immunised Individuals (full preventative vaccination confirmed)_

In this case, administration of immunoglobulin is not required. Two injections of vaccine should be administered at day 0 and day 3.

This schedule should not apply to immunocompromised individuals.

In both previously-immunised and non-immunised individuals, consideration should also be given to the possibility of tetanus and other wound infections, and appropriate measures taken as per the Current Immunisation Handbook.

_Paediatric use_

MIRV is indicated for use in paediatric population.

_Use in the elderly_

MIRV is indicated for use in elderly.
Method of administration

One dose consists of 1 mL of vaccine administered by the intramuscular route, in the deltoid area for adults and children or the anterolateral area of the thigh muscle in infants and toddlers.

For instructions on reconstitution of the medicine before administration, see section 6.6.

4.3 CONTRAINDICATIONS

Pre-Exposure

Known systemic hypersensitivity reaction to any component of MIRV see section 6.1 or after previous administration of the vaccine or a vaccine containing the same components.

Vaccination must be postponed in case of febrile or acute disease.

Post-Exposure

Since rabies infection generally results in death, there are no contraindications to post-exposure vaccination.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Do not administer intravenously or intradermally.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following administration of the vaccine.

As with any vaccine, vaccination with MIRV may not protect 100% of vaccinated individuals.

The full course of immunisation should be completed in order to obtain sustained antibody response.

As each dose may contain undetectable traces of neomycin which is used during vaccine production, caution must be exercised when the vaccine is administered to individuals with hypersensitivity to this antibiotic and other antibiotics of the same class.

Immunocompromised individuals

In individuals with congenital or acquired immunodeficiency, the immune response to the vaccine may be inadequate.

Therefore, it is recommended to monitor serological antibody level in such individuals to ensure that an acceptable response has been induced. Additional doses should be given as necessary.
Moreover, if post-exposure vaccination is needed, rabies immunoglobulin should be given in association with the vaccine for both categories II & III exposures.

**Bleeding Disorders**

Because intramuscular injection can cause injection site haematoma, MIRV should not be given to individuals with any bleeding disorder, such as haemophilia or thrombocytopenia, or to individuals on anticoagulant therapy unless the potential benefits clearly outweighs the risk of administration. If the decision is made to administer MIRV in such individuals, it should be given with caution, with steps taken to avoid the risk of haematoma formation following injection.

**Paediatric use**

MIRV is indicated for use in paediatric population.

**Use in the elderly**

MIRV is indicated for use in elderly.

**Effect on laboratory tests**

Interference of MIRV with laboratory and/or diagnostic tests has not been studied.

4.5 **INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION**

Corticosteroids and immunosuppressive treatments may interfere with antibody production and cause the failure of the vaccination. It is therefore advisable to perform a neutralizing antibody assay 2 to 4 weeks after the last injection.

When immunoglobulins against rabies are to be administered with rabies vaccine (see Dosage and Administration), they must not be combined in the same syringe or injected at the same site. If possible, the vaccine should be injected contra-laterally to the immunoglobulin administration sites.

4.6 **FERTILITY, PREGNANCY AND LACTATION**

**Pregnancy**

Category B2

**Pre-exposure**

The vaccine has not been studied in animal teratogenicity studies. Data on the use of this vaccine in pregnant women are limited. Therefore, the administration of the vaccine during pregnancy is not recommended.
For the vaccination of individuals at a high risk of exposure, the risk/benefit ratio must be assessed before administering the vaccine.

*Post-exposure*

Due to the severity of the disease, pregnancy is not a contraindication.

*Breast-feeding*

It is not known whether MIRV is excreted in human milk. Therefore, caution must be exercised when the vaccine is administered to a nursing woman.

*Fertility*

No data available.

### 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Not relevant.

### 4.8 UNDESIRABLE EFFECTS

Adverse event information is derived from clinical trials and worldwide post-marketing experience.

#### Data from Clinical Studies

Two studies where MIRV has been studied in randomised controlled trials in both children (N=199) using pre-exposure schedule (3 doses, IM) and adults (n=124) using the post exposure schedule (5 doses, IM) have been selected to represent safety clinical data.

*Blood and lymphatic system disorders*
  - Very common: adenopathy

*Immune system disorders*
  - Common: allergic reactions with skin disorders such as urticaria and rash, or respiratory manifestations such as dyspnoea and wheezing
  - Uncommon: angioedema

*Nervous system disorders*
  - Very common: headache
  - Common: dizziness
Gastrointestinal disorders
- Very common: nausea
- Common: abdominal pain, vomiting, diarrhoea

Musculoskeletal and connective tissue disorders
- Very common: myalgia
- Common: arthralgia

General disorders and administration site conditions
- Very common: injection site pain, erythema, and induration (swelling/hardness) hematoma, malaise
- Common: injection site pruritus (itching) fever, chills (shivering)

Data from Post-Marketing Experience
In addition, the following adverse events have been reported very rarely (<1/100000) during the post marketing surveillance of MIRV. Based on spontaneous reporting, their frequencies have been estimated using number of reports and estimated number of patients. However, exact incidence cannot be precisely calculated.

Immune system disorders
- Anaphylactic reactions
- Serum sickness type reactions

These reactions have been associated with the presence of betapropiolactone-altered human albumin in the Human Diploid Cell Vaccine (HDCV).

Nervous system disorders
- Paraesthesia
- Neuropathy
- Convulsion, encephalitis

General disorders and administration site conditions
- Asthenia

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/.
4.9 OVERDOSE

Not documented.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: antiinfectives for systemic use, ATC code: J07BG01.

Mechanism of Action

Following a single deep subcutaneous injection, an antibody response can be detected after a variable period of up to 7 days, in all subjects. Peak antibody levels are reached at about 30 days and then start to decline.

5.2 PHARMACOKINETIC PROPERTIES

No data available.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

MIRV has not been evaluated for genotoxic potential.

Carcinogenicity

MIRV has not been evaluated for carcinogenic potential.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Neomycin

Human serum albumin

Water for injections
6.2  INCOMPATIBILITIES
Not applicable.

6.3  SHELF LIFE
36 months.

6.4  SPECIAL PRECAUTIONS FOR STORAGE
Store refrigerated (2° to 8°C). Do not freeze.
Use immediately after reconstituting the vaccine.

6.5  NATURE AND CONTENTS OF CONTAINER
Vial (powder for reconstitution), 1 mL solvent (distilled water): 1's.
Box of 1 glass vial of lyophilised vaccine and 1 syringe of diluent.

6.6  SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING
Preparation

Reconstitution of vaccine:
Reconstitute the freeze-dried vaccine by introducing the diluent in the pre-filled syringe into the vial of powder. Shake carefully until complete suspension of the powder is obtained. Withdraw the suspension from the vial into a separate syringe, and administer via intramuscular injection with an appropriate needle for each individual.
Once reconstituted, the vaccine must be used immediately.
After use, any remaining vaccine and container must be disposed of safely, preferably by heat inactivation or incineration, according to locally agreed procedures.

7  MEDICINE SCHEDULE
Prescription Medicine
8 SPONSOR
sanofi-aventis new zealand limited
Level 8
56 Cawley St
Ellerslie
Auckland
New Zealand
Toll Free Number (medical information): 0800 283 684
Email: medinfo.australia@sanofi.com

9 DATE OF FIRST APPROVAL
7 April 1982

10 DATE OF REVISION OF THE TEXT
18 June 2018

Table 1 - Summary of Changes

<table>
<thead>
<tr>
<th>Section</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Format changes to align with new data sheet format</td>
</tr>
<tr>
<td>4.1</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>4.2</td>
<td>Updated to remove reference to obsolete booster recommendation.</td>
</tr>
<tr>
<td></td>
<td>Addition of detailed first aid treatment information, and vaccine and immunoglobulin administration for immunised and non-immunised individuals.</td>
</tr>
<tr>
<td>4.3</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>4.4</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>4.5</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>4.6</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>4.8</td>
<td>Aligned with CCDS.</td>
</tr>
<tr>
<td>5.1</td>
<td>Addition of ATC code. Text amended to remove reference to booster recommendation.</td>
</tr>
</tbody>
</table>